Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.C100745200 on January 17, 2002

J. Biol. Chem., Vol. 277, Issue 12, 9641-9644, March 22, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/12/9641    most recent
C100745200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kellner, D. G.
Right arrow Articles by Sligar, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kellner, D. G.
Right arrow Articles by Sligar, S. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ACCELERATED PUBLICATION
Kinetic Characterization of Compound I Formation in the Thermostable Cytochrome P450 CYP119*

David G. Kellner, Shao-Ching Hung, Kara E. Weiss, and Stephen G. SligarDagger

From the Departments of Biochemistry, Chemistry, and the College of Medicine, University of Illinois, Urbana, Illinois 61801

Received for publication, December 19, 2001, and in revised form, January 15, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The kinetics of formation and breakdown of the putative active oxygenating intermediate in cytochrome P450, a ferryl-oxo-(pi ) porphyrin cation radical (Compound I), have been analyzed in the reaction of a thermostable P450, CYP119, with meta-chloroperoxybenzoic acid (m-CPBA). Upon rapid mixing of m-CPBA with the ferric form of CYP119, an intermediate with spectral features characteristic of a ferryl-oxo-(pi ) porphyrin cation radical was clearly observed and identified by the absorption maxima at 370, 610, and 690 nm. The rate constant for the formation of Compound I was 3.20 (±0.3) × 105 M-1 s-1 at pH 7.0, 4 °C, and this rate decreased with increasing pH. Compound I of CYP119 decomposed back to the ferric form with a first order rate constant of 29.4 ± 3.4 s-1, which increased with increasing pH. These findings form the first kinetic analysis of Compound I formation and decay in the reaction of m-CPBA with ferric P450.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

P450 enzymes are ubiquitous in nature and carry out a wide range of important reactions including the activation of carbon centers for catabolism, steroid metabolism, and detoxification of xenobiotics (1). Due to the important physiological functions of P450 enzymes, the reaction intermediates of P450 chemistry have been a subject of investigation for many years. Several discreet steps occur in the hydroxylation chemistry of the cytochrome P450s including: substrate binding, first electron transfer to the P450 from a physiological redox partner, oxygen binding (to form oxy-P450), a second electron transfer event (to form a reduced oxy or peroxo state), proton transfer to the distal oxygen (forming hydroperoxo), and an oxygen scission event producing a putative high valent iron-oxo species that subsequently generates hydroxylated product (2). The high valent iron-oxo has long been thought to be analogous to the activated iron species characterized in other oxidative enzymes (horseradish peroxidase (HRP),1 catalase, and chloroperoxidase (CPO)) and referred to as Compound I, a ferryl-oxo-(pi ) porphyrin cation radical (3-5). The intermediates in the complex P450 reaction cycle have been gradually divulged through the use of a wide range of spectroscopic techniques (6-8) and the use of methods that allow access to the fast steps occurring after O2 binding (2, 9). Recently the peroxo and hydroperoxo intermediates have been observed through the use of cryo-enzymology techniques combined with radiolysis, generating these intermediates through gradual temperature annealing (2, 10). Although there has been no identification of a Compound I intermediate by these techniques, it has been inferred by indirect measurements (2, 11, 12). The Compound I state as well as the peroxo and hydroperoxo states of the enzyme have been proposed to be active in oxygenation events (13, 14).

To probe the nature of Compound I, meta-chloroperoxybenzoic acid (m-CPBA) has been used as an oxidizing agent to produce this high valent iron-oxo through heterolytic cleavage of the organic peroxide in CPO and HRP. The Compound I species of CPO and HRP have sufficient half-lives for resonance Raman and EPR studies and have been well characterized (3, 5, 15-17). The same peroxy acid and its derivatives have been used with P450s in attempts to generate intermediates. Evidence for the existence of Compound I in P450s was demonstrated through substrate oxygenation or hydroxylation in the reaction of various organic peroxides with either liver microsomal P450 or CYP101, respectively (18, 19, 21).

Contrary to the evidence for Compound I formation in cytochrome P450 using m-CPBA, Blake and Coon (20) reported that the reactions of several peroxy acids with CYP2B4 generated other active species, which are neither Compound I nor its one-electron-reduced adduct (Compound II). However, in previous studies the generation of the Compound I intermediate in cytochrome P450 (CYP101) required a large excess of peroxyacid, leading to the rapid formation, then conversion of Compound I to other species. This inherent reactivity of CYP101 from Pseudomonas putida has made the identification of Compound I tenuous, and, despite numerous efforts, kinetic analysis could not be completed in the 10-ms time regime of the intermediate's existence (21, 22).

To provide a characterization of the spectral properties of Compound I in a thiolate-liganded heme protein, Harris et al. calculated the spectrum of methylmercaptooxyferryl protoporphyrin IX using density functional theory (DFT) (23). The calculated spectrum had a split Soret blue shifted from the ferric Soret maximum by 60 nm with the Q bands appearing at 690 nm. Recently, Mössbauer and EPR spectroscopic studies of freeze-quenched samples from the reaction of m-CPBA with CYP101 demonstrated the existence of an organic radical and a ferryl species (24). The techniques employed were not fast enough to capture the Compound I intermediate on the path to the observed ferryl-radical species. Again, the high concentration of m-CPBA used in these studies leads to degradation of protein, which further complicates data analysis.

CYP119 is a thermostable P450 isolated from Sulfolobus solfataricus with a melting temperature of 91 °C and remarkable stability to pressure denaturation (25, 26). Thermostable enzymes are thought to have more rigid active site structures at room temperature than their mesophilic counterparts, which could lead to a slowing of individual steps in the catalytic cycle (27). This alteration in relative reaction rates may enable the resolution of intermediates that occur too rapidly to be characterized in their mesophilic counterparts.

CYP119 has proven to be an effective model system for the study of the intermediate states of the reaction cycle of this P450. For instance, we recently employed cryoenzymology to define the hydroperoxo state resulting from the one-electron reduction of the ferrous dioxygen state (28). In this communication, we report the reaction kinetics of ferric CYP119 with m-CPBA using stopped-flow spectroscopy and document the formation of a spectral intermediate with the characteristic spectrum of Compound I. The relevant time scales of formation and breakdown of Compound I in this thermophilic P450 are such that a kinetic characterization of these processes under various conditions can be obtained for the first time.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

m-CPBA was purchased from Aldrich-Sigma and purified using the method described by Davies et al. (29). Briefly, m-CPBA was re-crystallized in a 1:3 ether/petroleum ether solution and characterized by NMR. Solutions of m-CPBA for kinetic studies were prepared by addition of an acetone stock. The m-CPBA concentrations were determined by iodide oxidation to triiodide with the extinction coefficient of 25.5 mM-1 cm-1 at 353 nm (30).

Cytochrome P450 CYP119 expression and purification from Escherichia coli are as published previously (26, 31). Protein concentration was determined based on the Soret maximum at 415 nm (epsilon  = 104 mM-1 cm-1). All steady-state UV-visible spectra were recorded on a Hitachi U3300 spectrophotometer. Single wavelength stopped-flow measurements were performed on a KinTek (Austin, TX) model SF-2001 stopped-flow system at 4 °C. For multiple-wavelength absorption studies, a stopped-flow apparatus (model SX-18MV) and the associated computer system from Applied Photophysics (Surrey, UK) were used. Multiple-wavelength absorption studies were carried out using a photodiode array detector and X-SCAN software (Applied Photophysics, Ltd.). The dead-time of this instrument is about two milliseconds. In a typical experiment one syringe contained CYP119 (6 µM heme) buffered in 100 mM phosphate (at various pH), and the other contained various concentrations of m-CPBA. The reaction temperature was controlled by a water bath. Spectral deconvolution and kinetic analysis were performed by global analysis and numerical integration methods using PRO-K software (Applied Photophysics, Ltd.).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reaction kinetics of m-CPBA with ferric CYP119 were first obtained by following the decay of the ferric signal at 415 nm and a concurrent increase of absorption at 370 nm. Various m-CPBA/CYP119 concentration ratios were investigated, as shown in Fig. 1. At m-CPBA concentrations less than half that of the ferric protein, the absorption kinetics clearly show the formation of an intermediate by a second order process. The spectral intermediate then decays in a first order manner, with the spectrum returning to that of a ferric enzyme. At 21 µM CYP119 and an m-CPBA concentration of 1.25, 2.5, and 5 µM, the maximal observed absorbance change corresponds to 1, 2.1, and 3.4% of the total enzyme concentration, respectively. At higher m-CPBA concentrations, more complicated kinetic behavior was observed, with a broadband decrease in absorbance indicating protein decomposition (see "Discussion").


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Absorbance at 370 nm (A) and 415 nm (B) upon mixing ferric CYP119 with various m-CPBA concentrations (pH 7.0) and 4 °C. The final concentration of CYP119 after mixing was 21 µM, and the m-CPBA concentrations are: 20 µM (black-square), 10 µM (), 5 µM (), 2.5 µM (open circle ), and 1.25 µM (black-triangle).

Fig. 2 shows intermediate formation by the increase of absorption at 370 nm in the reaction of ferric CYP119 with a substoichiometric concentration of m-CPBA. The data (open circle ) are easily fit by a mechanism involving second order formation and first order decay (solid line, Reaction 1). Moreover, to assess the order of reactions (inset), the initial velocity of the intermediate formation was plotted against m-CPBA concentration, clearly showing the linear increase in velocity with increasing substrate concentration, indicative of a second order reaction. On the other hand, the decay rate constants obtained by the mechanism described above are within the range of 27-33 s-1 and independent of m-CPBA concentration for the reactions of 21 µM ferric CYP119 with 1.25, 2.5, and 5 µM m-CPBA. It is evident that the decomposition of this intermediate goes through a first order process under substoichiometric amount of m-CPBA. Note that at high m-CPBA concentrations there appears to be a departure from first order decomposition process, indicating a combination of protein destruction and side oxidation processes. To better characterize the first intermediate formed in this reaction, multi-wavelength kinetic measurements were carried out at low m-CPBA concentrations.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Time-dependent formation of the spectral intermediate upon rapid mixing of m-CPBA with CYP119. Stopped-flow data is shown (), along with curve fit of second order formation, first order decay mechanism (solid line); [CYP119] = 21 µM, [m-CPBA] = 5 µM. Initial velocity of Compound I formation (black-square) as a function of m-CPBA concentration is shown in the inset.

Rapid-scan stopped-flow spectrophotometry, together with singular value decomposition, was used to provide spectral identification of the observed intermediate. In this case, full spectra as a function of time were analyzed using the following model.
<UP>CYP119 </UP>(<UP>ferric</UP>)+m-<UP>CPBA</UP> <LIM><OP><ARROW>→</ARROW></OP><UL>k<SUB><UP>1</UP></SUB></UL></LIM><UP> Intermediate I</UP> <LIM><OP><ARROW>→</ARROW></OP><UL>k<SUB><UP>2</UP></SUB></UL></LIM><UP> CYP119 </UP>(<UP>ferric</UP>)

<UP>R<SC>eaction</SC> 1</UP>
The spectra of the ferric protein and Intermediate I as well as the kinetic trace of each species involved were resolved (Fig. 3). As indicated, rapid mixing of m-CPBA with CYP119 produced a spectral intermediate (solid line, Fig. 3A) with absorbance maxima at 370, 610, and 690 nm. This spectrum is indicative of a Compound I state of the enzyme, as shown by the DFT calculations from Harris et al. (23).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   Spectra and kinetics from the reaction of CYP119 with m-CPBA. A, calculated spectra of ferric CYP119 (dashed line) and Intermediate I (solid line) using the Pro-K fitting program (see "Experimental Procedures"). Shown is the average of 24 individually calculated spectra. Experimental conditions: [CYP119] = 16.25 µM, [m-CPBA] = 7 µM (pH 7), 4 °C. B, the corresponding kinetic traces of ferric CYP119, m-CPBA, and Compound I obtained from global fitting are shown as dashed line, dotted line, and solid line, respectively.

The formation of Compound I at a ratio of m-CPBA to protein of 1:2.5 (pH 7.0) had a second order rate (k1) of 3.20 (± 0.3) × 105 M-1 s-1, and a first order decomposition rate (k2) of 29.4 ± 3.4 s-1. When m-CPBA concentrations were higher than the concentration of CYP119, protein decay occurred in multiple complicated kinetic processes.

To probe the role of proton concentration on Compound I formation, the reaction between CYP119 and m-CPBA was studied as a function of pH by means of multi-wavelength measurements. The rates of formation and decay for compound I in CYP119 at different pH are shown in Table I. Additionally, the rates of formation and decay for Compound I were increased with an increase in reaction temperature. The Arrhenius plot (data not shown) for the Compound I formation reaction (k1) equates to an Ea = 14.1 kcal/mole and the decay rate (k2) Ea = 18.1 kcal/mol.

                              
View this table:
[in this window]
[in a new window]
 
Table I
The observed second order formation (k1) and first order decomposition (k2) rate constants of CYP119 Compound I at various pH values


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The thermostable cytochrome P450 CYP119 has proven to be an excellent system for investigating the nature of intermediates with higher oxidation states of this important class of heme proteins. Previous attempts to form and isolate a Compound I intermediate in CYP101 and other P450s were hampered by the use of a large excess of peroxyacids, leading to rapid progression from Compound I to other intermediates and concomitant protein destruction (21, 24). The formation of Compound I in CYP119 was slowed both by the use of lower concentrations of m-CPBA and by the temperature at which the experiments were carried out (4 °C), which was well below the physiological temperature for this thermophilic enzyme (80 °C). This allowed the detection of an intermediate clearly defined as Compound I well within the time scale accessible by stopped-flow spectroscopy. Protein degradation, which can often complicate kinetic analysis, was largely avoided. These properties of Compound I formation in CYP119 have made the spectral and kinetic characterization of this previously elusive chemical species in P450s possible.

CYP119 is capable of forming an intermediate with the spectral characteristics of a Compound I, ferryl-oxo-(pi ) porphyrin cation radical, when rapidly mixed with the peroxy acid m-CPBA. The spectral similarities of the CYP119 Compound I to the optical spectra of Compound I in other heme proteins are summarized in Table II. The Soret band of this Compound I was asymmetric and single-peaked at 370 nm (Fig. 3A), while asymmetric Soret bands of both CYP101 and CPO are at 367 nm (21, 32). This asymmetric feature has been deconvoluted using Gaussian-type transition bands and assigned as the splitting Soret band of the d-type hyper-porphyrin in the recent spectroscopic studies of CPO Compound I (16). Moreover, the visible spectrum of CYP119 Compound I has almost identical absorption intensity at 610 and 690 nm, whereas the intensity at 610 nm of CPO Compound I is lower than its absorption at 688 nm. Overall, these findings indicate the similarity between the Compound I entity of these two thiolate-ligated heme proteins and the minor differences in the absorption spectra can be attributed to their electronic structure differences. Similar spectral characteristics of P450 Compound I have also been generated from DFT calculations by Harris et al. (23). The calculated spectra of the methylmercaptooxyferryl protoporphyrin IX model structure are blue-shifted by 50-60 nm in both the ferric resting state and Compound I; however, the other features and the peak shapes are quite similar to the results presented here. The major peak in the split Soret band of the calculated Compound I spectrum is blue-shifted from the ferric Soret by 60 nm, similar to the 45 nm shift in the CYP119 Compound I. Additionally, the Q-bands of the calculated Compound I are shifted to 690 nm, with the equivalent bands in the same location for CYP119 Compound I. 

                              
View this table:
[in this window]
[in a new window]
 
Table II
Comparison of the absorption maxima (in nm) of Compounds I and II for various heme proteins

The reaction of CYP101 with m-CPBA was shown by Egawa et al. (21) to form an intermediate with spectral characteristics similar to those of CYP119 Compound I. However, this intermediate was formed in the dead-time of the stopped-flow instrument used and decomposed rapidly into a series of unidentified intermediates. The high concentration of peracid used also caused breakdown of the protein. The experimental conditions necessary to generate the putative Compound I in CYP101 included the use of a 30-fold excess of m-CPBA, increasing the formation rate to the point that the intermediate was fleetingly formed and rapidly decayed. The Compound I, formed under the conditions presented here, in CYP119 has a half-life more than an order of magnitude longer than the apparent CYP101 half-life with high concentrations of m-CPBA. This longer half-life has allowed the first kinetic characterization of the formation and decomposition processes for Compound I in a P450. To compare the reaction kinetics of CYP119 Compound I with other heme proteins, rate constants for Compound I formation and decay in various systems are summarized in Table III. While the Compound I states of the other three proteins are stable enough to detect at room temperature, characterization of a P450 Compound I species necessitated the utilization of a thermophilic protein and low temperature (4 °C).

                              
View this table:
[in this window]
[in a new window]
 
Table III
The formation (k1) and decomposition (k2) rate constants of Compounds I of several heme proteins

The kinetic competence in the conversion of the observed intermediate to an oxygenated product would be a valuable piece of information. Unfortunately, the physiological substrate for this enzyme is not known. However, the addition of laurate to the reaction mixture in a double mixing configuration after the addition of m-CPBA leads to complete quenching of the observed spectral intermediate within the dead-time of the instrument. The reaction of a Compound I intermediate with juxtaposed substrate has been suggested to be very fast, and hence we do not expect to directly observe the kinetic conversion to product. Analysis of the reaction mixture following addition of laurate in this double-mix experiment demonstrated the presence of hydroxylaurate as a product (data not shown), suggesting the coupling of intermediate decay to substrate oxygenation.

The pH dependence for Compound I formation reflects the pK of m-CPBA of 7.4. Previous data have shown that the protonated form of m-CPBA is the active species for Compound I formation, leading to increased rates of Compound I formation at lower pH (20). The pH dependence of the m-CPBA reaction with CYP119 is similar to the behavior of catalase reacting with peroxyacetic acid (33). In both cases the results are most simply interpreted as a reaction between the enzyme and non-ionized peroxy acid molecules. This is substantiated by similar pH dependence for the reaction between peroxybenzoic acid and horseradish peroxidase (29). Additionally, the Ea for Compound I formation (14.1 kcal/mol) in CYP119 is relatively high compared with the reaction of hydrogen peroxide with peroxidases (2.5-5 kcal/mol) that utilize hydrogen peroxide as a substrate (34). This is in agreement with the recent findings for the reaction of prostaglandin endoperoxide synthase with hydrogen peroxide, which also has an elevated Ea (~24 kcal/mol) of its Compound I formation and does not use hydrogen peroxide as a native substrate (35).

The disappearance of CYP119 Compound I is a first order process. This makes it unlikely that the degradation of Compound I involves O2 formation by nucleophilic attack of a second m-CPBA molecule as observed in chloroperoxidase (32). Similarly, the possibility of the formation of Compound II from the reaction of Compound I with a second peroxy acid molecule as in HRP can be ruled out. One possibility is that the oxene oxygen is transferred to the protein. Alternatively, it has been suggested that the slow regeneration of the ferric state in catalase, from Compound I, is carried out by a reducing equivalent originating from the protein matrix (33, 36). The CYP119 Compound I decays to the low-spin ferric form at a rate about 105 times faster than that of catalase Compound I. These active species can be reduced by any adventitious reducing equivalent from the protein matrix (4). The pH dependence of the Compound I decomposition rate is similar to the decay of ferryl intermediate in cytochrome c oxidase, which was explained by an auto-reduction pathway (37). Taken together, the mechanism of degradation of CYP119 Compound I and the regeneration of the ferric enzyme can only be determined with more experimental analysis.

The kinetic characterization of Compound I formation in CYP119 has allowed for the optimization of conditions for the maximal production of this putative reaction intermediate in time regimes accessible to other spectroscopic methods. The information thus obtained will aid in the further determination of the nature of Compound I in P450 reactions.

    ACKNOWLEDGEMENTS

We thank Prof. Robert Gennis and Dr. Joel Morgan for the use of their Applied Photophysics rapid scanning stopped-flow spectrophotometer.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants GM 31756 and GM 33775.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: School of Molecular and Cellular Biology, 505 S. Goodwin Ave., University of Illinois at Champaign-Urbana, Urbana, IL 61801. Tel.: 217-244-7395; Fax: 217-265-4073; E-mail: s-sligar@uiuc.edu.

Published, JBC Papers in Press, January 17, 2002, DOI 10.1074/jbc.C100745200

    ABBREVIATIONS

The abbreviations used are: HRP, horseradish peroxidase; CPO, chloroperoxidase; m-CPBA, meta-chloroperoxybenzoic acid; DFT, density functional theory.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Guengerich, F. P. (2001) Chem. Res. Toxicol. 14, 611-650[Medline] [Order article via Infotrieve]
2. Davydov, R., Makris, T. M., Kofman, V., Werst, D. E., Sligar, S. G., and Hoffman, B. M. (2001) J. Am. Chem. Soc. 123, 1404-1415
3. Palaniappan, V., and Terner, J. (1989) J. Biol. Chem. 264, 16046-16053[Abstract/Free Full Text]
4. Benecky, M. J., Frew, J. E., Scowen, N., Jones, P., and Hoffman, B. M. (1993) Biochemistry 32, 11929-11933[CrossRef][Medline] [Order article via Infotrieve]
5. Hosten, C. M., Sullivan, A. M., Palaniappan, V., Fitzgerald, M. M., and Terner, J. (1994) J. Biol. Chem. 269, 13966-13978[Abstract/Free Full Text]
6. Lipscomb, J. D. (1980) Biochemistry 19, 3590-3599[CrossRef][Medline] [Order article via Infotrieve]
7. Yu, C. A., Gunsalus, I. C., Katagiri, M., Suhara, K., and Takemori, S. (1974) J. Biol. Chem. 249, 94-101[Abstract/Free Full Text]
8. Bangcharoenpaurpong, O., Rizos, A. K., Champion, P. M., Jollie, D., and Sligar, S. G. (1986) J. Biol. Chem. 261, 8089-8092[Abstract/Free Full Text]
9. Denisov, I. G., Makris, T. M., and Sligar, S. G. (2001) J. Biol. Chem. 276, 11648-11652[Abstract/Free Full Text]
10. Davydov, R., Macdonald, I. D. G., Makris, T. M., Sligar, S. G., and Hoffman, B. M. (1999) J. Am. Chem. Soc. 121, 10654-10655[CrossRef]
11. Aikens, J., and Sligar, S. G. (1994) J. Am. Chem. Soc. 116, 1143-1144[CrossRef]
12. Schlichting, I., Berendzen, J., Chu, K., Stock, A. M., Maves, S. A., Benson, D. E., Sweet, R. M., Ringe, D., Petsko, G. A., and Sligar, S. G. (2000) Science 287, 1615-1622[Abstract/Free Full Text]
13. Raner, G. M., Hatchell, A. J., Morton, P. E., Ballou, D. P., and Coon, M. J. (2000) J. Inorg. Biochem. 81, 153-160[CrossRef][Medline] [Order article via Infotrieve]
14. Vaz, A. D. N., Kessell, K. J., and Coon, M. J. (1994) Biochemistry 33, 13651-13661[CrossRef][Medline] [Order article via Infotrieve]
15. Egawa, T., Miki, H., Ogura, T., Makino, R., Ishimura, Y., and Kitagawa, T. (1992) FEBS Lett. 305, 206-208[CrossRef][Medline] [Order article via Infotrieve]
16. Egawa, T., Proshlyakov, D. A., Miki, H., Makino, R., Ogura, T., Kitagawa, T., and Ishimura, Y. (2001) J. Biol. Inorg. Chem. 6, 46-54[CrossRef][Medline] [Order article via Infotrieve]
17. Kincaid, J. R., Zheng, Y., Al-, Mustafa, J., and Czarnecki, K. (1996) J. Biol. Chem. 271, 28805-28811[Abstract/Free Full Text]
18. Guengerich, F. P., Vaz, A. D. N., Raner, G. N., Pernecky, S. J., and Coon, M. J. (1997) Mol. Pharmacol. 51, 147-151[Abstract/Free Full Text]
19. Sligar, S. G., Shastry, B. S., and Gunsalus, I. C. (1976) in Microsomes and Drug Oxidations (Ullrich, V. , Roots, I. , Hildebrandt, A. , Estabrook, R. W. , and Conney, A. H., eds) , pp. 204-205, Pergamon Press, Oxford
20. Blake, R. C. I., and Coon, M. J. (1989) J. Biol. Chem. 264, 3694-3701[Abstract/Free Full Text]
21. Egawa, T., Shimada, H., and Ishimura, Y. (1994) Biochem. Biophys. Res. Commun. 201, 1464-1469[CrossRef][Medline] [Order article via Infotrieve]
22. Wagner, G. C., Palcic, M. M., and Dunford, H. B. (1983) FEBS Lett. 156, 244-248[CrossRef][Medline] [Order article via Infotrieve]
23. Harris, D., Loew, G., and Waskell, L. (2001) J. Inorg. Biochem. 83, 309-318[CrossRef][Medline] [Order article via Infotrieve]
24. Schünemann, V., Jung, C., Trautwein, A. X., Mandon, D., and Weiss, R. (2000) FEBS Lett. 479, 149-154[CrossRef][Medline] [Order article via Infotrieve]
25. Tschirret-Guth, R. A., Koo, L. S., Hui Bon Hoa, G., and Ortiz de Montellano, P. R. (2001) J. Am. Chem. Soc. 123, 3412-3417[CrossRef][Medline] [Order article via Infotrieve]
26. McLean, M. A., Maves, S. A., Weiss, K. E., Krepich, S., and Sligar, S. G. (1998) Biochem. Biophys. Res. Commun. 252, 166-172[CrossRef][Medline] [Order article via Infotrieve]
27. Michels, P. C., Clark, and Douglas, S. (1997) Appl. Environ. Microbiol. 63, 3985-3991[Abstract]
28. Denisov, I. G., Hung, S. C., Weiss, K. E., McLean, M. A., Shiro, Y., Park, S. Y., Champion, P. M., and Sligar, S. G. (2001) J. Inorg. Biochem. 87, 215-226[CrossRef][Medline] [Order article via Infotrieve]
29. Davies, D. M., Jones, P., and Mantle, D. (1976) Biochem. J. 157, 247-253[Medline] [Order article via Infotrieve]
30. Ramette, R. W., and Sandford, R. W. (1965) J. Am. Chem. Soc. 87, 5001-5005[CrossRef]
31. Maves, S. A., and Sligar, S. G. (2001) Protein Sci. 10, 161-168[CrossRef][Medline] [Order article via Infotrieve]
32. Hager, L. P., Doubek, D. L., Silverstein, R. M., Hargis, J. H., and Martin, J. C. (1972) J. Am. Chem. Soc. 94, 4364-4366[CrossRef][Medline] [Order article via Infotrieve]
33. Jones, P., and Middlemiss, D. N. (1972) Biochem. J. 130, 411-415[Medline] [Order article via Infotrieve]
34. Marklund, S., Ohlsson, P. I., Opara, A., and Paul, K. G. (1974) Biochim. Biophys. Acta 350, 304-313[Medline] [Order article via Infotrieve]
35. Bakovic, M., and Dunford, H. B. (1996) Biochem. Cell Biol. 74, 117-124[Medline] [Order article via Infotrieve]
36. Pfister, T. D., Gengenbach, A. J., Syn, S., and Lu, Y. (2001) Biochemistry 40, 14942-14951[CrossRef][Medline] [Order article via Infotrieve]
37. Fabian, M., and Palmer, G. (2001) Biochemistry 40, 1867-1874[CrossRef][Medline] [Order article via Infotrieve]
38. Araiso, T., Rutter, R., Palcic, M. M., Hager, L. P., and Dunford, H. B. (1981) Can. J. Biochem. 59, 233-236[Medline] [Order article via Infotrieve]
39. Rodriguez-Lopez, J. N., Hernández-Ruiz, J., Garcia-Cánovas, F., Thorneley, R. N. F., Acosta, N., and Arnao, M. B. (1997) J. Biol. Chem. 272, 5469-5476[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. Tejero, A. Biswas, Z.-Q. Wang, R. C. Page, M. M. Haque, C. Hemann, J. L. Zweier, S. Misra, and D. J. Stuehr
Stabilization and Characterization of a Heme-Oxy Reaction Intermediate in Inducible Nitric-oxide Synthase
J. Biol. Chem., November 28, 2008; 283(48): 33498 - 33507.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Newcomb, J. A. Halgrimson, J. H. Horner, E. C. Wasinger, L. X. Chen, and S. G. Sligar
Reactive Oxygen Species Special Feature: X-ray absorption spectroscopic characterization of a cytochrome P450 compound II derivative
PNAS, June 17, 2008; 105(24): 8179 - 8184.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Sudhamsu and B. R. Crane
Structure and Reactivity of a Thermostable Prokaryotic Nitric-oxide Synthase That Forms a Long-lived Oxy-Heme Complex
J. Biol. Chem., April 7, 2006; 281(14): 9623 - 9632.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. C. Glascock, D. P. Ballou, and J. H. Dawson
Direct Observation of a Novel Perturbed Oxyferrous Catalytic Intermediate during Reduced Putidaredoxin-initiated Turnover of Cytochrome P-450-CAM: PROBING THE EFFECTOR ROLE OF PUTIDAREDOXIN IN CATALYSIS
J. Biol. Chem., December 23, 2005; 280(51): 42134 - 42141.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. L. Stone, R. K. Behan, and M. T. Green
X-ray absorption spectroscopy of chloroperoxidase compound I: Insight into the reactive intermediate of P450 chemistry
PNAS, November 15, 2005; 102(46): 16563 - 16565.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Spolitak, J. H. Dawson, and D. P. Ballou
Reaction of Ferric Cytochrome P450cam with Peracids: KINETIC CHARACTERIZATION OF INTERMEDIATES ON THE REACTION PATHWAY
J. Biol. Chem., May 27, 2005; 280(21): 20300 - 20309.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C.-H. Yun, K.-H. Kim, M. W. Calcutt, and F. P. Guengerich
Kinetic Analysis of Oxidation of Coumarins by Human Cytochrome P450 2A6
J. Biol. Chem., April 1, 2005; 280(13): 12279 - 12291.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. Schunemann, F. Lendzian, C. Jung, J. Contzen, A.-L. Barra, S. G. Sligar, and A. X. Trautwein
Tyrosine Radical Formation in the Reaction of Wild Type and Mutant Cytochrome P450cam with Peroxy Acids: A MULTIFREQUENCY EPR STUDY OF INTERMEDIATES ON THE MILLISECOND TIME SCALE
J. Biol. Chem., March 19, 2004; 279(12): 10919 - 10930.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. T. Groves
Bioinorganic Chemistry Special Feature: The bioinorganic chemistry of iron in oxygenases and supramolecular assemblies
PNAS, April 1, 2003; 100(7): 3569 - 3574.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. H. Lim, J.-U. Rohde, A. Stubna, M. R. Bukowski, M. Costas, R. Y. N. Ho, E. Munck, W. Nam, and L. Que Jr.
Bioinorganic Chemistry Special Feature: An FeIV==O complex of a tetradentate tripodal nonheme ligand
PNAS, April 1, 2003; 100(7): 3665 - 3670.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
J.-U. Rohde, J.-H. In, M. H. Lim, W. W. Brennessel, M. R. Bukowski, A. Stubna, E. Munck, W. Nam, and L. Que Jr.
Crystallographic and Spectroscopic Characterization of a Nonheme Fe(IV)&cjs0811;O Complex
Science, February 14, 2003; 299(5609): 1037 - 1039.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/12/9641    most recent
C100745200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kellner, D. G.
Right arrow Articles by Sligar, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kellner, D. G.
Right arrow Articles by Sligar, S. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement